| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Baricitinib (JAN/USAN/INN); Olumiant (TN) | ||||||||
| Product | OLUMIANT (Eli Lilly and Company) | ||||||||
| Other | BARICITINIB (Eli Lilly and Company) | ||||||||
| Formula | C16H17N7O2S | ||||||||
| Exact mass | 371.1164 | ||||||||
| Mol weight | 371.4169 | ||||||||
| Structure |  | ||||||||
| Class | Anti-inflammatory DG01985 Disease modifying anti-rheumatic drug (DMARD) DG02020 JAK inhibitor Transporter substrate DG01665 ABCB1 substrate DG01913 ABCG2 substrate DG02860 SLC22A8 substrate DG03002 SLC47A2 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Anti-inflammatory, Antirheumatic, Immunosuppressant, Janus kinase (JAK) inhibitor | ||||||||
| Disease | Rheumatoid arthritis [DS:H00630] | ||||||||
| Comment | Treatment of autoimmune diseases, inflammatory disease, rheumatoid arthritis | ||||||||
| Target | JAK1 [HSA:3716] [KO:K11217] JAK2 [HSA:3717] [KO:K04447] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLC22A8 [HSA:9376], SLC47A2 [HSA:146802] | ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L04 IMMUNOSUPPRESSANTS L04A IMMUNOSUPPRESSANTS L04AA Selective immunosuppressants L04AA37 Baricitinib D10308 Baricitinib (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Immunological Agents Immunological Agents, Other JAK Inhibitor Baricitinib D10308 Baricitinib (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 39 Other agents affecting metabolism 399 Miscellaneous 3999 Others D10308 Baricitinib (JAN/USAN/INN) Drug groups [BR:br08330] Anti-inflammatory DG01985 Disease modifying anti-rheumatic drug (DMARD) DG02020 JAK inhibitor D10308 Baricitinib Transporter substrate DG01665 ABCB1 substrate D10308 Baricitinib DG01913 ABCG2 substrate D10308 Baricitinib DG02860 SLC22A8 substrate D10308 Baricitinib DG03002 SLC47A2 substrate D10308 Baricitinib Drug classes [BR:br08332] Immunological agent DG02020 JAK inhibitor D10308 Baricitinib Antirheumatic agent DG01985 Disease modifying anti-rheumatic drug (DMARD) D10308 Baricitinib Target-based classification of drugs [BR:br08310] Protein kinases Non-receptor tyrosine kinases JAK family JAK1 D10308 Baricitinib (JAN/USAN/INN) <JP/US> JAK2 D10308 Baricitinib (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10308 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10308 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10308 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10308 Drug metabolizing enzymes and transporters [br08309.html] Drug transporters D10308 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 26 1 C8y C 21.8059 -18.3269 2 C8y C 21.8059 -19.7308 3 N5x N 20.6126 -20.4327 4 C8x C 19.3491 -19.7308 5 N5x N 19.3491 -18.3269 6 C8y C 20.6126 -17.6250 7 C8x C 23.1396 -17.9057 8 C8x C 23.9819 -19.0288 9 N4x N 23.1396 -20.1519 10 C8y C 20.6126 -16.2211 11 C8x C 19.4895 -15.3787 12 N4y N 19.9107 -14.1152 13 N5x N 21.3146 -14.1152 14 C8x C 21.7357 -15.3787 15 C1z C 18.7174 -13.4133 16 C1x C 17.8049 -12.3604 17 N1y N 16.7519 -13.2729 18 C1x C 17.6645 -14.3258 19 C1b C 19.6299 -12.3604 20 C3b C 21.1040 -12.3604 21 N3a N 22.5079 -12.3604 22 S4a S 15.3481 -13.2729 23 O3c O 15.3481 -11.8690 24 O3c O 15.3481 -14.6768 25 C1b C 13.9442 -13.2729 26 C1a C 13.2422 -12.0572 BOND 29 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 1 7 1 8 7 8 2 9 8 9 1 10 2 9 1 11 6 10 1 12 10 11 2 13 11 12 1 14 12 13 1 15 13 14 2 16 10 14 1 17 15 12 1 18 15 16 1 19 16 17 1 20 17 18 1 21 15 18 1 22 15 19 1 23 19 20 1 24 20 21 3 25 17 22 1 26 22 23 2 27 22 24 2 28 22 25 1 29 25 26 1 |